Abstract: Compounds of the formulas: wherein: R1-R4, X1, Y1, and A are as defined herein are provided. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds are useful for the treatment of a disease or disorder. In some embodiments, the disease or disorder is a proliferative disease such as cancer.

Abstract: A method for processing lignin may comprise flowing a lignin composition comprising a lignin polymer and a solvent through a reaction chamber of a continuous flow reactor, the lignin polymer comprising hydroxycinnamic groups bound to a polymeric backbone; flowing ozone through the reaction chamber containing the lignin composition under conditions to maximize oxidative cleavage of the hydroxycinnamic groups to produce one or more types of aromatic monomers while minimizing oxidative cleavage of the polymeric backbone; and collecting the one or more types of aromatic monomers, e.g., by a size-selective membrane separation device.

Abstract: A process for the ozonolysis of an alkane may comprise combining an alkane and ozone in a liquid phase medium comprising CO2 under conditions sufficient to oxidize the alkane to produce one or more non-combustion products. The liquid phase medium may be free of a super acid.

Abstract: Embodiments are directed to identifying active compounds for a targeted medium from a library of compounds. In one scenario, a computer system receives high throughput screening (HTS) data for a subset of compounds that have been HTS-screened. The computer system determines labels for a subset of compounds based on labels identified in the HTS-screened compounds as being part of an active class or part of an inactive class, access chemical features corresponding to the HTS-screened compounds, apply Fuzzy logic membership functions to calculate membership values for active and inactive compounds to determine the degree to which each compound belongs to the active class or to the inactive class, train an artificial neural network (ANN) to identify active compounds in silico based on the Fuzzy logic membership functions, and process another subset of compounds in silico to identify active and inactive compounds using the trained artificial neural network.

Abstract: The present invention is related to compositions comprising decellularized cartilage tissue powder in the forms of paste, putty, hydrogel, and scaffolds, methods of making compositions, and methods of using these compositions for treating osteochondral defects and full- or partial-thickness cartilage defects.

Abstract: Cosmetic and dietary supplement compositions containing silymarin and sulfoalkyl ether cyclodextrin, particularly sulfobutyl ether cyclodextrin, are described. The compositions and methods are useful in reducing appearance of facial redness in rosacea-prone skin, rejuvenating skin, preventing skin aging, inhibiting oxidative stress in epidermal and dermal cells, increasing collagen production, reducing the likelihood of skin cancer, treating or reducing liver damage from a toxin, or treating a liver disease.

Abstract: Compounds of the formulas are provided: wherein variables Y1-Y5, X1-X5, A1-A4, X, y, n1, n2, and R1-R15 are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds are useful for the treatment of a disease or disorder, including, for example, a proliferative disease, such as cancer.

Abstract: Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds have the following structure: in which Z is an oxadiazole. The compounds disclosed are useful in treatment of fibrotic disease, particularly renal fibrosis, and similar diseases associated with the dysregulation of the HIPK2/Smad3 signaling pathway.

Abstract: A compound can be a pro-fluorophore peroxynitrite sensor that generates a fluorophore when cleaved by peroxynitrite, having a structure of Formula A: wherein: moiety A is an ER-targeting fluorophore; Y is a linker; and moiety B is a phenol, substituted or unsubstituted, wherein the structure of Formula A is less fluorescent than the ER-targeting fluorophore moiety A.

Abstract: Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR8 agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae described herein or derivative thereof.

Abstract: A method of promoting hair growth can include: a polypeptide having a sequence that has at least 75% complementarity to or at least 75% identical to SPR4; and topically administering the polypeptide to a subject. This can include putting or causing the polypeptide to be in the skin, such as in any dermal layer. In one aspect, the method can include administering the composition topically so as to administer the polypeptide to the subject. In one aspect, the method can include administering the polypeptide to skin of the subject. In one aspect, the method can include administering the polypeptide to a hair follicle of the subject. In one aspect, the method can include administering the polypeptide to a bald spot of the subject.

Abstract: A pharmaceutical composition can include: a marmelin analog compound, and a pharmaceutically acceptable carrier having the compound. The compound can be present in a therapeutically effective amount to treat or inhibit a disease state. The disease state can be cancer. The cancer can be selected from brain cancers, head and neck cancers, thyroid cancers, gastrointestinal cancers, esophageal cancers, stomach cancers, pancreatic cancers, liver cancers, colo-rectal cancers, lung cancers, kidney cancers, prostate cancers, bladder cancers, testicular cancers, breast cancers, ovarian cancers, cervical cancers, and melanomas. The carrier includes a cyclodextrin, which may form a complex with the compound. The compounds and compositions can be used to treat or inhibit progression of cancers. Colo-rectal, bladder, and prostate cancers are examples of some of the cancers that can be treated with the marmelin analog compounds.

Abstract: Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral neuropathy.

Abstract: Methods for forming tunnel barrier layers are provided, including a method comprising exposing a surface of a material, the surface free of oxygen, to an initial water pulse for a pulse time and at a pulse temperature, the pulse time and pulse temperature selected to maximize hydroxylation of the surface; and exposing the hydroxylated surface to alternating, separated pulses of precursors under conditions to induce reactions between the hydroxylated surface and the precursors to form a tunnel barrier layer on the surface of the material via atomic layer deposition (ALD), the tunnel barrier layer having an average thickness of no more than 1 nm and being formed without an intervening interfacial layer between the tunnel barrier layer and the surface of the material.

Abstract: Provided herein are compounds of the formulas: (I) wherein: n, X2, R3, R3?, R4, R4?, R5, R5?, R6, and R6? are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used for the treatment of diseases, including diabetic peripheral neuropathy or cancer.

Abstract: A fluid sensing device includes an outer body having a fore side, an aft side, and an interior space, the outer body including a fluid inlet disposed at the fore side; an inner body extending at least partially out of the fluid inlet of the outer body along a longitudinal axis; one or more vents disposed aft of the fluid inlet to allow passage of fluid through the fluid sensing device; and at least one load sensor coupled to the inner body to measure a fluid drag force on the inner body, wherein the inner body is configured to induce the Coanda effect in at least a portion of a fluid contacting the inner body at an angle transverse to a longitudinal axis of the inner body.

Abstract: The present disclosure relates to devices and methods for delivery of a ferrofluid to a targeted treatment site, such as delivery of a ferroadhesive to a pathological fistula to occlude the fistula. A device includes a catheter having a lumen and a distal opening. A hollow solenoid is coupled to a distal section of the catheter, and a hollow core of the solenoid allows passage of a ferrofluid through the catheter and through the hollow core so that it may exit past the distal end of the hollow solenoid. The solenoid may be selectively actuated to maintain or control the position of the delivered ferrofluid.

Abstract: An aerial vehicle includes a body having a longitudinal axis, a plurality of movable members emanating connected to the body, at least one motor, and at least three aerodynamic propulsors driven by the at least one motor. The movable members are connected to the body and extend away from the body.

Abstract: Antigenic molecules and compositions described herein protect against infection by typhoidal and non-typhoidal Salmonella serovars. Methods of immunization comprise the use of the antigenic molecules.

Abstract: An implant can include a plurality of polymeric fibers associated together into a fibrous body. The fibrous body is capable of being shaped to fit a tracheal defect and capable of being secured in place by suture or by bioadhesive. The fibrous body can have aligned fibers (e.g., circumferentially aligned) or unaligned fibers. The fibrous body can be electrospun. The fibrous body can have a first characteristic in a first gradient distribution across at least a portion of the fibrous body. The fibrous body can include one or more structural reinforcing members, such as ribbon structural reinforcing members, which can be embedded in the plurality of fibers. The fibrous body can include one or more structural reinforcing members bonded to the fibers with liquid polymer as an adhesive, the liquid polymer having a substantially similar composition of the fibers.